Lumexa Imaging Holdings, Inc. (LMRI) Earnings Call Transcript
May 12, 2026
Earnings Call Speaker Segments
Thanks, and good day, everyone; glad you could be with us. Our Chief Executive Officer, Caitlin Zulla, and Tony Martin, our CFO, are heading up today's call. Before we get started, I'd like to point out that we'll be covering non-GAAP financial measures that we believe are useful when assessing Lumexa's performance. The press release on our website contains the details on how those measures tie to our GAAP figures, as well as reconciliations. In addition, we'll be sharing forward-looking statements grounded in what we currently expect and assume, and those carry risks and uncertainties, among them the factors set out in our press release and in the various filings we make with the SEC. Actual results might differ materially, and we take on no obligation to update any of these forward-looking statements. So with that, let me hand things over to Caitlin. Caitlin, the floor is yours.
Thanks, Sue. I appreciate everyone being here today. During the first quarter, we achieved a number of significant milestones as we began the year carrying out our strategic priorities. Those priorities involve generating robust same-center expansion with a growing blend of advanced modalities, aiming for a record quantity of de novo launches, making sure newly opened centers ramp up successfully, speeding up high-impact strategic service lines, and broadening our geographic reach. Below are several key points from what we announced this evening. Our Q1 performance matched what we anticipated following the seasonal and weather-related factors we talked about on our Q4 call. Volume levels during Q1 built up across March, and we regained our forward momentum. To be specific, we produced robust same-center expansion, and strategic service lines are growing within a healthy blend of advanced modalities. During Q1, advanced modalities increased 7% compared with the prior year, with PET up 23.1% year-over-year and MRI up 8.2% year-over-year. Deployment of our AI-driven breast arterial calcification offering is ongoing, with intentions to move into additional markets and sustained strong adoption by patients. We are vigorously ramping de novo centers, and our 2024 and 2025 cohorts are performing as we anticipated while moving our plans forward toward long-term growth and profit expansion. In some thrilling news this evening, we have finished 2 acquisitions and launched 2 de novos so far this year, and we are firmly on track to reach our stated target of opening 8 to 10 de novos to power future growth. Importantly, one acquisition involved an IDTF site located in Pennsylvania — the inaugural site in our new JV with UPMC — and we are actively pushing forward multiple site location plans alongside this key partner. Lastly, we are delighted to welcome 2 outstanding leaders to Lumexa, both of whom bring the depth of experience and vision that will assist in propelling our next chapter of growth and results. I will provide a bit more detail shortly. Here at Lumexa, we are tackling a sizable market opportunity and applying a disciplined growth algorithm; we feel confident that we are well positioned to carry out our growth plans while generating improved outcomes throughout the imaging landscape. I want to take a moment to discuss our market experience as we meet with health systems and the providers who matter so much to us, and as we proceed with our commercial efforts to boost growth in acuity mix. Our value proposition connects powerfully with patients, providers, and payers, as shown by Net Promoter Scores that regularly surpass 90. We provide high-quality imaging in more convenient locations, on a more prompt schedule, and at a substantially lower cost than hospital outpatient departments, which helps health systems address key operational difficulties and fulfill their patient care and market expansion objectives. As we chase our priorities, it is evident that the market is shifting in our direction; we are gaining from lasting long-term tailwinds, aging populations, new treatment paradigms that require advanced imaging, increasing preventative screening rates, and a continuing transition from inpatient to outpatient care within a fragmented, capacity-constrained industry. When we spoke with a number of prospective health system partners, they described dealing with imaging constraints that limit operational volume and push back when patients can get care. That highlights how badly outpatient capacity is needed, plus rising interest in a collaborator capable of providing speed, access and capital-efficient expansion. Meanwhile, a lot of systems are getting ahead of possible site neutrality by speeding up their move toward cheaper outpatient locations, and we think that only strengthens how relevant our model is; they also say they appreciate our agile best-of-breed strategy, which guarantees we can keep harnessing innovation to generate efficiency along with the strongest patient experience and outcomes. As I noted earlier, given the substantial growth opportunity we are chasing at Lumexa, we are happy to bring aboard 2 experienced leaders. To start, Kyle Lynch, who becomes our Chief Growth Officer, arrives with extensive background creating high-performing business development organizations, completing complicated transactions and carrying out growth strategies that turn into lasting financial results. And Rikki Mondo, another established industry veteran, has come to Lumexa as Chief Enterprise Operations Officer. Rikki possesses a solid history of leading and scaling national platforms to generate performance, integration and operational excellence. As our growth continues, her emphasis on enterprise-wide alignment will prove essential for delivering to our patients, partners and teams. Welcome, Kyle and Rikki. We could not be more excited to have both of you on our team, helping push disciplined, efficient and sustainable growth via joint ventures, de novo development, acquisitions and commercial growth initiatives. Now, briefly, on the core components of our growth algorithm. Our commercial team remains entirely focused on generating same-center growth. Right after a successful New Jersey launch, we broadened our AI-powered breast arterial calcification program into New York. And across both markets, acceptance has been strong for this cash add-on assessment covering cardiac health in women. Our team kept their attention on advancing imaging. For us, PET and MRI count as strategic priorities. Extra seasonal campaigns aimed at gastroenterologists and ENT specialists were timed for the beginning of allergy season. Those help drive our growth and lift acuity mix in Q1. We remain on track to widen our geographic footprint via new de novo openings, JV partnerships and carefully chosen M&A. Tonight's announcement highlights the opening of 4 new Lumexa imaging centers, among them 2 small yet strategic tuck-in acquisitions, which shows how strong our JV partnerships are. Pennsylvania hosts the first location with UPMC, while the second sits in North Carolina with Advocate Health. Over time the acquired facilities will ramp, as will their integration into our operating platform, once we finish payer enrollment requirements. South Carolina and Florida are home to the 2 new de novos, extending our footprint in appealing MSAs and moving us closer to our target of opening 8 to 10 de novos annually and producing profitable growth. On the M&A side, specifically tuck-in purchases of additional centers, there's substantial opportunity for us to apply what we know to a fragmented market and speed up our footprint in chosen geographies. We're always looking at accretive possibilities using a proven, disciplined method; regarding JVs, beyond our enthusiasm about the UPMC partnership that's ramping up, we're building a strong pipeline of prospective health system partners, with numerous conversations underway at different stages; from what health system leaders tell me, it's obvious that how we handle joint ventures sets us apart as a company. Systems want a way to take part in the fast shift of care sites toward outpatient imaging and to expand their outpatient ambulatory footprint. Our JV approach offers a very effective way in, thanks to the clinical, commercial and operational excellence we show, especially in de novo development. Lumexa Imaging is positioned well to assist systems in delivering on those ambitions even as they stay concentrated on their wider enterprise priorities. These partnerships, in exchange, speed up our footprint in whatever market we're in. Last, a word about what we're doing to scale the company efficiently. We're always chasing efficiency improvements so we can handle rising outpatient imaging volume and make use of our installed base of centers and equipment inside them. FastScan integration kept rolling out across our centers, and by the close of 2026 we're aiming for 2/3 adoption. We're also making good use of virtual cockpit for remote MRI scanning, letting us reduce the effect of machine downtime, flex staffing schedules, and lengthen our hours to serve patients; and we keep pushing ahead with our plan to use technology and AI throughout support services functions to drive scale as we keep growing. As I wrap up my remarks, I want to mention briefly that a vendor of ours recently had a cybersecurity incident involving a breach of Lumexa data. Sadly, events like this have grown more and more frequent across industries. Our patients always come first, and we're completely dedicated to doing right by them; we responded quickly and are taking the required steps to handle the situation, safeguard our patients and comply with applicable laws and regulations. Importantly, we've examined the situation and its effects, and we don't think it has a material impact on our business or financial results. In the spirit of transparency, we wanted you to know. Because of the nature of the event, we can't say more right now and we will, of course, give updates later as we have them. To wrap up, I'm pleased with our Q1 results; we head into Q2 with confidence driven by strong execution and a feeling that at Lumexa Imaging, we're in the early innings of capitalizing on the opportunities ahead of us. Our mission inspires us — extending access to high-quality imaging through elevated compassionate care, improving lives and advancing health care across the country. Ahead of handing things to Tony so he can walk everyone through our first quarter in greater depth, I'd like to express enormous gratitude to the committed people on our team and our radiologists. So, Tony, go ahead.
Thanks, Caitlin, and I appreciate everyone being with us today. During this call, I'll go over the financial results and discuss several main factors behind how we performed in the quarter. After that, I'll share our outlook for the full year 2026. To go along with my review of our GAAP financials today, I'll reference certain system-wide metrics so you can gain a clearer picture of how the business is doing overall and how broad it is. System-wide metrics cover every center we run, whether owned by us or operated through our 8 joint ventures with health systems. Now to our first quarter financials. Consolidated revenues reached $253 million, which is up 3% from the prior-year period. System-wide revenue growth, covering every site we operate, came to 4% for the quarter, roughly 2/3 driven by volume and 1/3 from rate, a mix that matches the way we model the company. Revenue per unit, covering both scan and read revenue, likewise rose, thanks to advanced modalities making up a larger share of our business plus some ongoing gain from modestly higher contracted rates with payers who value our lower price point relative to hospital-based services; we saw robust system-wide performance at all our outpatient sites, both wholly owned and within JVs, and we remain happy with the business's core performance. Advanced modality volumes, which reimburse 3 to 4x more than routine modalities, rose 7% against the prior year on both a consolidated and system-wide basis. As we mentioned on our Q4 call, a mix of factors shaped our first quarter volumes: a strong Q4 seasonal showing that produced greater seasonality as we entered Q1, along with weather-related disruptions in Q1 that briefly affected patient volumes at several of our sites. On the whole, those factors wound up hitting Q1 EBITDA by roughly $4 million, in line with what we expected. Advanced modalities got back to being the fastest growing and rose 7% for the quarter, carrying strong momentum as we head into Q2. Overall, system-wide volume growth was 2.5%, as the strength in advanced was offset by routine scans, which came in essentially flat, with mammography needing more time to rebound following the storms. Although routine scans contribute less to our earnings than advanced, we're happy to see them building back up, which adds to our confidence about our annual performance. Beyond that, our payer mix moves in a predictable seasonal way. Q4 reliably shows the strength of our commercial book as patients pursue care before deductible resets, while Q1 naturally brings a relative shift toward our government book as that commercial activity returns to normal. As is true for many other health care service providers, we saw somewhat more payer mix seasonality in Q1 '26 than in Q1 '25, with a slight decline in commercial as a share of total system-wide revenues. Now I'll give some further detail on our consolidated revenues. Outpatient net patient service revenues came in at $138 million, up 4%, driven by same-site growth plus new de novos from the 2024 and 2025 cohorts that are still ramping. Professional fee revenues — our second operating segment — totaled $59 million, which was a 1% increase. And management fee and other revenues rose 5%, reaching $55 million. Of that management fee figure, about $21 million comes from management fees tied to running the sites within our health system JVs. Typically, that's calculated as a percentage of site revenues. The other $34 million under this category consists of 0 margin pass-throughs for employee, IT, and site level costs that we cover on our joint ventures' behalf. So as you build your models, grasping these 2 components matters for understanding the margin impact. G&A came to $20 million for the quarter, which is $3 million above the first quarter of 2025. That reflects $7 million of higher expenses tied to combined public company costs and stock-based comp. That increase was partly offset by roughly $4 million of reductions in certain transaction-related costs, along with timing differences in G&A expense between Q1 and later quarters. Pubco costs, consistent with the guidance we provided, totaled $1.2 million in the quarter and are building toward a full year impact of $7 million. Stock-based compensation climbing from $6 million in Q1 '25 to $12 million in Q1 '26 stems from resetting legacy equity comp plans in connection with our December IPO; that pushes expected stock-based comp for the full year to approximately $50 million. Half of that $50 million ties to historic M&A and will be fully amortized by the end of 2026. Looking forward, then, we anticipate ongoing stock-based compensation of roughly $20 million to $28 million per year, beginning in 2027. Quarterly amounts could fluctuate based on vesting timing. Below operating expenses, we include equity and earnings of unconsolidated affiliates; that's our pro rata ownership share of net income from our JV sites, and at $15 million it was flat year-over-year, in line with how the business performed overall. Below the operating line, interest expense for Q1 was $16 million. This new run rate sits $14 million below Q1 '25, thanks to our use of IPO proceeds to pay down debt, which frees up more than $50 million in cash annually that we intend to put toward growth. Pretax income was $3 million for Q1 '26, versus a pretax loss of $4 million in Q1 '25. We're a cash taxpayer now, so following a tax provision of $1 million in the quarter, net income was $2 million in Q1 '26, compared with a net loss of $8 million in the prior year period. In the first quarter, GAAP EPS came to $0.02 per share, while adjusted earnings per share stood at $0.18. Turning now to adjusted EBITDA — a metric we consider a key gauge of how our whole company is performing operationally, and one that shows how solid our financial model is. Contributions flow into our adjusted EBITDA from our pro rata share of EBITDA across every site we have, including the ones wholly owned by us and those held in Health Systems JVs. Revenue stayed robust during the quarter, especially from advanced modalities, yet adjusted EBITDA landed at $51.2 million — unchanged from $51.1 million in the prior-year period, though matching what we had anticipated. Seasonality played a role here, along with weather-driven softness in volumes, set against a cost base that is only partly variable, such as staffing and facility expenses that don't move in proportion to near-term swings in volume, particularly when weather disruptions hold down daily scan counts. Even with those site-level dynamics, and the $1.2 million increase in public company costs, our adjusted EBITDA margin reached 20.3% in Q1 '26, versus 20.8% in Q1 '25. Just like earnings, adjusted EBITDA margin is typically at its lowest point early in the year, then climbs as the months go on. Before I turn to cash flows, let me take a moment on our joint ventures and the way they appear in our reported figures. We see our JV structures as straightforward, capital-efficient ways to grow the business while producing meaningful cash flows for both us and our health system partners — an amount that closely mirrors our income from these JV sites.
Joint ventures help us broaden our brand and advance our goal of providing outstanding patient care, opening up greater availability of top-tier imaging. You can find specifics about how our JVs perform financially in the quarterly financial statement disclosures we release. To put it simply, though, because we hold a minority stake, JV revenues and expenses don't show up in our GAAP results. What does appear in our adjusted EBITDA is our pro rata portion of JV EBITDA, which captures how the assets we hold are actually operating and brings our EBITDA in line with the genuine size of our business. Take a case where our stake in a JV is 49% and that JV produces $20 million of EBITDA — for us, the system-wide EBITDA contribution from it would come to $9.8 million. Cash also gets distributed to us by our JVs. Those distributions appear in free cash flow under distributions from unconsolidated affiliates, a distinct line item within our cash flows from operating activities. Since these cash receipts already account for any JV CapEx, we don't call out JV CapEx separately when discussing cash flows. The debt held by these JVs doesn't sit on our balance sheet and is made up of equipment lease financing amounting to $82 million. Healthy operating cash flow is something our business produces. Because of typical seasonal shifts in working capital plus the seasonality of volumes and earnings, the first quarter tends to be the weakest one for cash flow during the year. That means cash flows, much like our earnings, typically build up as the quarters progress. Cash flows from operating activities came to $3 million in Q1 '26. That's a $17 million gain versus Q1 '25, mostly thanks to reduced interest payments resulting from refinancing our debt and our IPO last December. Free cash flow — which we define as cash flows from operating activities minus CapEx — was negative $2 million in Q1 '26, a $13 million gain versus Q1 '25. Moving on to CapEx and our thinking around it. As we said when we went public, during 2026 and 2027 we see a substantial chance to speed up our growth plans within our fragmented industry and earn meaningful returns by putting money into de novos, new and upgraded equipment at our current sites, and through focused M&A. The $5 million we spent on capital in Q1 2026 shows how we intend to grow the business in a disciplined way; on top of that, we financed capital expenditures through lease arrangements, which boosts our capital efficiency. Broadly speaking, as we invest for growth, we presently anticipate free cash flow in 2026 to land somewhere around 25% to 30% of our adjusted EBITDA on a full year basis, and we believe it will climb higher as we gain scale and once spending on our growth initiatives and infrastructure to scale the company comes back to more typical levels. Naturally, CapEx can fluctuate between quarters because of working capital timing or other strategic uses of capital we spot from time to time. To address something we're occasionally asked: our JVs handle their own capital expenditures. When it comes to our operating cash flows, what our JVs do is completely captured there already. The sites in those JVs bring in operating cash, spend on capital projects, cover equipment lease obligations, and afterward send us our share, on a pro rata basis, of whatever cash remains — that's the thing I called distributions from unconsolidated affiliates. You'll see it as one line item within our cash flows from operating activities. That wraps up, so let's move to guidance. The seasonal and weather effects of Q1 are now behind us, and with solid growth in advanced modalities, robust demand, better capacity, plus what ramping JVs and de novos are contributing, we're in a good spot to meet our commitments for the full year. Driven by those factors, our expectation for revenue remains $1.045 billion to $1.097 billion, and for adjusted EBITDA, $234 million to $242 million, a figure that includes roughly $7 million in public company costs that weren't incurred in 2025. Taking the midpoint, if you set aside the addition of those costs from our first full year of operations as a public company, the adjusted EBITDA growth rate would come to 7%. Adjusted EPS, we expect, will land between $0.71 and $0.77 per share. A bit more detail: throughout the remaining 3 quarters, we anticipate a gradual sequential climb in adjusted EBITDA, with most of the full year's adjusted EBITDA arriving in the back half as we push same-center growth, geographic expansion, broader strategic service lines, and efficiencies throughout our company. Looking toward Q2 and continuing to execute against our goals, the opportunities ahead have us energized. With that said, let's take your questions. Operator, please open the call.
Perhaps starting with the UPMC deal. I'm just wondering, should we view it this way — that within the UPMC joint venture you could speed up the ramp the same way you do with start-up acquisitions, in order to build scale alongside that partner?
Yes. Thanks a lot, Brian. We're incredibly thrilled to kick off the UPMC joint venture by acquiring a facility, and this is definitely something that will keep fueling the expansion of our partnership. Together with UPMC, we're actively moving site planning forward and anticipate being able to announce at least a few de novos with them during this year. As a reminder, the JV partnership with UPMC became official around August, September of last year. And so usually it's simpler to get a de novo off the ground. So we're excited to already have an acquisition behind us and then to keep backing it up with de novos this year and into next year too.
Brian, thanks. And Tony, picking up on what you said near the close of your prepared remarks regarding EBITDA building gradually across the year — could you tell us how we ought to frame the size of that seasonal bump in Q4? And also, what would drive margins, and how should we think about margin movement starting in Q1 and continuing right through Q4?
Yes, absolutely. To begin with, we stay confident in our full year guidance, which is unchanged. As for the stronger seasonality we mentioned a few weeks back, our view is that it will keep climbing steadily, just as it does annually, though it begins from a somewhat lower level in Q1. So the way I see it now, roughly 55% of our adjusted EBITDA should land in the back half of the year — not a big difference from what we said before, perhaps a shift of 100 basis points versus our initial expectations for how it would be distributed. That said, that's our read on how this seasonality will unfold. We feel really good about it given all our strengths, especially in advanced modalities as we head into Q2. Naturally, results tend to rise quarter by quarter once the annual deductible reset gets things going at the start of the year. Plus, with all our de novos, we have 15 opened just since late 2024, and every one of those is ramping up throughout the year. That contributes to why it's spread that way across the year.
Therefore, the $4 million EBITDA effect combined across 1Q, stemming from that pull-forward of volume plus the drag tied to weather. You described this year's seasonality influence as enhanced — could you give us some context regarding how the weather effect this year, or the two combined, stacks up against prior years? Also, is the size of that drag, measured against 1Q earnings, bigger than what we'd typically see? Answer from J.
Martin: Yes. Yes. What I'd say is that weather is simply a reality, and it forms a piece of this business, which means forecasting it accurately is hard; nonetheless, yes, for us this year it played a more significant role than it typically does. We had 4 distinct weather occurrences, and those mattered quite a bit across a number of markets. So no, we would not call that exactly a typical year, yet it's the sort of thing you normally have to work through whenever it comes up. That, then, forms one element of the heightened seasonality that we've been observing.
Understood. Then, as a follow-up, regarding the full-year guidance and the volume recapture assumptions — how much of that has already occurred between 2Q and 4Q to offset part of the 1Q volume that was lost? Or put differently, what portion of those volumes does your guidance treat as already rebooked, and what portion is still expected to perhaps be recaptured later in the year?
Well, a substantial amount of the advance business has already come back to us. That was the quickest to return; and naturally, we're very pleased about that, since it represents the higher reimbursement, higher-margin business and an ever-larger share of our book. So that returned first. Certain routines were slower to recover, and we'll be ramping into Q2 and Q3. But mainly, the ramp is driven simply by deductibles resetting at the start of the year and how that unfolds across the year for a great many health care service providers. There's a natural build in the business leading toward the strongest performance coming in Q4. So that occurs fairly steadily as the year progresses. And then, naturally, the de novos as well — there are so many of them at this point, 15 that are ramping extremely well. Every one of them is at or above what we expected, and they're only building momentum quarter-by-quarter throughout 2026. So that's an additional reason we hold a lot of confidence in where we're headed as the year unfolds.
This is Matthew Mardula, filling in for Ryan Daniels. Could you give us an update on what share of MRI machines right now are equipped with the FastScan software technology? And then, more broadly, how do you expect to go about adding FastScan software to MRI machines? Is it weighted more toward the second half? Any detail on that? And then, for the machines where FastScan software was deployed during this quarter, how does the early lift in capacity and volume stack up against what you had anticipated internally?
Yes. Thank you so much, Matt. I appreciate that question. Looking at our advanced growth, the Q1 performance is something we feel great about — 7% across both system-wide and consolidated. In the earnings script, we highlighted PET growing more than 23% compared to last year, which is pretty impressive, along with MRI at 8.2%. As you mentioned, FastScan is a major factor behind that solid MRI growth. Wherever we're able, we keep installing FASTScan throughout our fleet, either via upgrades or system enhancements. We entered the year at 51%, and I believe we stated we'd reach slightly above 66% to 67% of our MRI fleet having FastScan by year-end, and we're very much on pace to hit that. Turning to how the centers are doing with FastScan, results have been quite strong. Our team keeps working on ways to make scheduling more efficient, and one figure that really shows the momentum is that advanced made up 37.4% of our overall volume in Q1. That marks a gain of 160 basis points compared with Q1 2025, and it tops any quarter from last year. So this is an area we're fully dedicated to expanding.
I simply want to be certain we get the CapEx cash flow issue fully clarified; therefore, disregarding capital lease accounting, what should we expect regarding debt PP&E at year-end and cash flow, whether or not capital leases finance it?
Yes, I appreciate the question. Regarding CapEx, our estimate is roughly $5 million to $7 million each quarter, which means a total for the entire year somewhere between the mid- and upper 20s. And like you mentioned, we do finance a portion on top of that, so no cash leaves the door for it. That figure is likely close to the same amount I just mentioned, yet no cash goes out for it.
All right. Moving on to my next one — I might be the one struggling to keep up here — but those 4 centers you just told us about, had they been included in the UPMC arrangement as part of your bigger-picture strategy? Or did they come in as brand-new sites within that whole thing?
Yeah. Thanks very much, Don. So of the 4 centers, 2 came as single sites, 1 alongside UPMC, and then 1 alongside Advocate Atrium. The other 2 are de novos, and both of those we own entirely, with 1 located in South Carolina and 1 located in Niceville, Florida. As it happens, I got the chance to go see the one in Niceville, Florida; it opened just last week. It's a gorgeous building. The team there is amazing, and we're already seeing plenty of interest from the community plus a genuinely robust schedule. So in terms of de novos, we've got 2 finished and performing well, on pace to reach the 8 to 10 prior to year-end. Then as for UPMC, it began with an acquisition, and after that the UPMC de novos are going to be part and parcel of that 8 to 10.
This quarter, your operating cash flow came in at roughly $3 million, while free cash flow stood at negative $2 million. Based on what you're guiding, it sounds like quarterly free cash flow should climb past $20 million. Could you take us through the pieces and what's driving that pickup in free cash flow?
Sure, sure. Yeah, cash flow always bottoms out at the beginning of the year, for much the same reasons the overall business does — volumes and earnings; on top of that, working capital is usually a drag early in the year. Bonus and benefit plan funding is weighted unevenly toward the first half. So historically, Q1 and Q2 are the slow quarters for cash flow in this business, and we're expecting the same this year. Then it steps up meaningfully in the back half, once that working capital timing pressure is behind us. And naturally, the underlying business is building too.
Understood. All right, then it'll be weighted toward the second half. Moving on — perhaps my next question concerns net revenue per scan. Looking at same-store figures, net revenue per scan rose 2.3% consolidated, yet system-wide it increased just 1%. That suggests unconsolidated net revenue per scan acted as a drag and might even have turned negative this quarter. Could you explain what's behind that softness in unconsolidated revenue per scan, particularly since advanced volume growth brings a favorable mix effect?
Yes. Yes; and advanced is an enormously effective engine for our business across both the JV structures and the consolidated ones, especially within the JV structures. I believe we usually concentrate largely on system-wide metrics here, since the business may perform differently on the consolidated book compared with JVs, and that doesn't truly have to signify much for the business. So I'd concentrate on that system-wide component above all. I think our — having said that, our consolidated book of business feels somewhat more impact from other modalities. It isn't as heavily concentrated in advanced. And thus, based on how those modalities perform, if routine is sluggish within that book of business, then advanced shines even brighter when it comes to lifting the rate per scan. That's the sort of phenomenon we witness in quarters such as this one, where routine was somewhat slower to recover than the advanced modalities were.
Is there a way to quantify the size of the 2 acquisitions that closed during the quarter? And is there any explanation for why they might be bigger or smaller than the typical center?
Yeah. Appreciate it, Whit. To respond to that directly, for a standard-sized acquisition, when we consider the contribution within the year, a major priority for us at this moment is bringing them into the network and completing all the credentialing and integration tasks. Frankly, we purchase sites that need optimization. The reason we acquire them is their potential, not because they are already optimized. So once the site is in network, we have to get the proper equipment installed and push patient volumes up to the Lumexa standard; therefore, regarding the impact, these facilities will build up gradually across the year, but I anticipate their contribution in 2026 will be quite minimal. And I'm thrilled because they show the strength of our model and truly position us for 2027 and beyond.
Okay. Then perhaps regarding the tech angle, is there anything you'd like to highlight, Caitlin — anything fresh involving revenue cycle, or matters affecting operations, that has you especially enthusiastic?
Thank you. Technology across every dimension is thrilling within our industry. When we consider tech and AI, it genuinely keeps slotting into those fundamental buckets. In what ways are we enhancing our primary operations, attracting additional patients, treating a greater number of patients using the same machine, how do we generate back-office operating efficiencies, how do we grow our strategic service lines and naturally, how do we assist our radiologists along with their productivity. We observe evidence across each of those buckets. The emphasis remains squarely on the operational front, carrying on with FastScan's rollout, we addressed Matt's question, broadening adoption of virtual MRI. Revenue cycle, still developing bots and Agentic agents, also covering our scheduling, the centralized scheduling team. Regarding strategic service lines, we introduced breast arterial calcification across 2 of our markets, plus we're actively looking into other comparable cash pay add-ons for modalities such as CT and ultrasound. Then on the clinical side, to help radiologists, we keep working with tools such as Ferrum, which is our clinical algorithm convener, followed by RAD Pair and RAD AI to aid abnormality identification, physician dictation and drafting. So plenty of enjoyable things. My perspective is that the near term stays heavily centered on boosting productivity and efficiency. And afterward the long term will remain centered on how we fuel reimbursable revenue growth.
I wanted to inquire regarding that roughly $4 million figure for transient items this quarter. Is there possibly a drag on same-store revenue, or perhaps a decremental margin, that you could provide as modeling assumptions tied to that $4 million? Any general insight into how that $4 million estimate came together would be useful. Then I have one more question.
Absolutely. Yes, that figure reflects our projection of how much greater seasonality hit us, with storms accounting for a large portion, though some of it is simply intrinsic to the business; we did recover a substantial share of that volume during the quarter. So on the revenue side, things turned out robust, especially for Advance. Absent the storm, Advance would have performed even more impressively for us. Thus revenue-wise, we recouped much of it, yet margin pressure exists, as the flat EBITDA shows. That is simply the cost of seeing patients through such a period. At the site, our cost structure is somewhat fixed, covering rent, equipment payments, and we compensate technologists per shift instead of per scan. So a fixed element exists that genuinely helps us when volumes spike. However, on storm days when certain patients arrive and others cannot, we treat everyone possible. Still, with a somewhat fixed cost structure and fewer daily scans for a period, that hurt our margin somewhat. Yet it is solid business to have, and we remain happy to provide it, serve our patients, and earn some profit from it, though margin was slightly impacted. And that is fine; it comes with the territory.
Okay, understood. And then, I suppose, if we added that $4 million back, it would point to an EBITDA growth rate of roughly 8% for the quarter. And I think that implies the remainder of the year has to grow about 4% year-over-year. So it seems like you're pretty much on track, but at the same time, the implied second quarter guidance, if you look at the 45%, I think might perhaps put you on pace for flatter year-over-year EBITDA once again as we get to the second quarter. I suppose what would really help is to get a handle on how that shift plays out, what the growth rate looks like, and whether we should be factoring in anything on the cost side as things scale up — could be public company expenses, could be something else.
Yeah, you're definitely right to focus on what that implies for how we're thinking about Q2 and the periods after it. Some seasonality is still going to be part of the picture, so you'll see a gradual increase. At the midpoint, Q1 comes in at 21.5% of our annual adjusted EBITDA. Then for Q2, based on what I laid out — 45% of earnings arriving in the first half and 55% in the second half — that works out to roughly 23.5% of the full year coming from Q2. So it's a consistent rise, though not a dramatic one. Yeah, I'd say our position is strong for pulling that off. Then in Q3 and Q4, with the business growing on its own plus the JVs and de novos ramping up, you'll see those numbers climb steadily too, and Q4 is really where it all comes together.
Kieran here, filling in for Pito. Could you go a bit deeper on what you said about payer mix — specifically what you observed during the quarter? I get that seasonality plays a role, but did anything unusual show up, whether from HIX or elsewhere?
Yes. Kieran, thanks for asking. Nothing we're seeing in reimbursement or the payer landscape amounts to a meaningful shift. What happened in Q1 matched typical seasonality, especially with deductible resets, plus a short-lived move in payer mix away from commercial and toward Medicare. As for HIX, it remains a modest piece of our business. Nothing notable is showing up there either. Looking at the broader picture, we keep gaining from occupying that lower-cost position in care, definitely when compared with hospital outpatient departments, and we stay appealing to payers, patients, and health systems. So on reimbursement and payer matters, we feel quite confident about both the stability and the positioning of the business.
Great, and I just have one more question. I believe you mentioned that PET growth came in at 23%. That's a fairly strong pickup compared with, at minimum, how the full year 2025 ended up. So could you bring us up to speed on what trends showed up during the quarter regarding volume and utilization throughout your fleet, and more broadly, what you're seeing when it comes to referrals and demand? Also, are there any pressure points involving radio tracers or similar items?
Yes. Thanks for asking; the substantial year-over-year increase in PET of 23% quarter-over-quarter during Q1 has us really enthusiastic. During the roadshow and in a lot of our discussions with all of you, we covered the chance we have to expand PET; we're starting from a modest base, and our PET expansion remains on schedule. We're bringing in additional machines, with those additions slated for 2026. Beyond that, teams throughout the company are developing approaches to speed up PET's growth even more in 2026 and afterward — whether that comes from fresh marketing efforts, new uses, isotopes, tracers, as you mentioned, or further new locations.
To wrap up, I'd like to express appreciation for the people on our team along with the radiologists we work with — their dedication to what we're trying to accomplish, and to the patients and communities that depend on us, is still what everything we do is built on. Thanks for the questions you brought today. As we head into Q2, we've got strong momentum, a strategy that's clear, and a great deal of confidence in our capacity to deliver, and we're eager to share news about how things are going down the road. Wishing everyone a good night.
Appreciate it, everyone, for joining us on today's call — that brings the program to a close. You're welcome to hang up now. Have a good day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Lumexa Imaging Holdings, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Lumexa Imaging Holdings, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.